Detalles de la búsqueda
1.
Population Pharmacokinetics and Dosing Simulations for Aripiprazole 2-Month Ready-to-Use Long-Acting Injectable in Adult Patients With Schizophrenia or Bipolar I Disorder.
Clin Pharmacol Drug Dev
; 13(6): 631-643, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38602057
2.
Safety and efficacy of aripiprazole 2-month ready-to-use 960 mg: secondary analysis of outcomes in adult patients with bipolar I disorder in a randomized, open-label, parallel-arm, pivotal study.
Curr Med Res Opin
; 39(7): 1021-1030, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37272079
3.
Safety and Efficacy of Aripiprazole 2-Month Ready-to-Use 960 mg: Secondary Analysis of Outcomes in Adult Patients With Schizophrenia in a Randomized, Open-label, Parallel-Arm, Pivotal Study.
J Clin Psychiatry
; 84(5)2023 09 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37672016
4.
A Randomized, Open-Label, Multiple-Dose, Parallel-Arm, Pivotal Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Aripiprazole 2-Month Long-Acting Injectable in Adults With Schizophrenia or Bipolar I Disorder.
CNS Drugs
; 37(4): 337-350, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36961650
5.
Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison.
Neuropsychiatr Dis Treat
; 19: 1409-1416, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37313228
6.
Putative coiled-coil structural elements of the BBA68 protein of Lyme disease spirochetes are required for formation of its factor H binding site.
J Bacteriol
; 187(4): 1317-23, 2005 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-15687195
Resultados
1 -
6
de 6
1
Próxima >
>>